1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Bavarian Nordic CEO 'Seeking Big Pharma partner' For RSV Vaccine Program

 
• By Sten Stovall

Phase II trials of Bavarian Nordic’s MVA-BN RSV prophylactic vaccine suggest it boosts memory responses against RSV in patients with a poor underlying immunity. Phase III trials may begin in 2020.

RSV
Phase II data suggest a single shot of MVABN RSV induces a broad potent immune response • Source: Shutterstock

Bavarian Nordic AS of Denmark hopes to de-risk planned Phase III studies of its MVA-BN RSV prophylactic vaccine by first running a human challenge trial in collaboration with contract research organization SGS to generate better efficacy data for the therapy, the Danish group's CEO told Scrip.

The planned human challenge – or the controlled human infection model – would be conducted in parallel with the Danish vaccine maker's talks with regulatory authorities on the eventual design of Phase III trials for the respiratory syncytial virus (RSV) vaccine, designed to target five

More from Clinical Trials

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

More from R&D

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.